Instem PLC said on Tuesday it has secured funding from the European Medicines Agency related to the research of N-nitrosamines, carcinogens humans may consume through tobacco use or eating certain foods.
The European Medicines Agency invested €2.5 million into the research, with Instem receiving 13% of that.
The IT solutions provider, serving life sciences market, is working on a two-year research project to further investigate the mutagenicity of different classes of N-nitrosamines, funded by EMA and led by Fraunhofer Institute for Toxicology & Experimental Medicine.
NAs may be carried by active pharmaceutical ingredients as impurities from production and/or storage or may cause their formation in the gastrointestinal tract.
The project will aim to distinguish highly potent from less potent carcinogens.
Instem shares were up 0.2% at 676.40 pence on Tuesday afternoon in London.
Copyright 2022 Alliance News Limited. All Rights Reserved.
